Additions and Corrections

2002, Volume 45

Le Wang,* Keith W. Woods, Qun Li, Kenneth J. Barr, Richard W. McCroskey, Steven M. Hannick, Laura Gherke, R. Bruce Credo, Yu-Hua Hui, Kennan Marsh, Robert Warner, Jang Y. Lee, Nicolette Zielinski-Mozng, David Frost, Saul H. Rosenberg, and Hing L. Sham: Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation.

Page 1704. Table 4 and Figure 3 contained some errors. In Table 4, all four "mg" units in the column head should be "μg" and there should be a center dot in the unit "μg·h/mL" for AUC. In Figure 3, the compound listed in the inset should be **25f**. The following are the corrected table and figure.

Table 4. Pharmacokinetic Studies in Dog, Monkey, and Mouse on Compounds **24h** and **25f**[a]

	24h			**25f**		
	C_{max} (μg/mL)	AUC (PO) (μg·h/mL)	F (%)	C_{max} (μg/mL)	AUC (PO) (μg·h/mL)	F (%)
dog	1.87	7.05	44.5	4.15	9.65	45.8
monkey	0.354	0.98	12.5	9.68	43.98	91.2
mouse	0.25	0.82	24.2	5.52	3.82	89.7

[a] Two animals used for each dosing group (oral and iv, 5 mg/kg); the PK parameters reported here were the average of two animals.



Figure 3. Regression trial of **25f** against murine M5076 reticulum sarcoma cell line.

JM020332+

10.1021/jm020332+
Published on Web 09/19/2002